Clinical features and prognosis of recurrent endometrial carcinoma Stages Ⅰ and Ⅱ

屠铮,商宇红,富琪,王建六,魏丽惠

DOI: https://doi.org/10.13390/j.issn.1672-1861.2003.02.012

2003-01-01

Abstract:Objective To explore the clinical features and prognosis of recurrent endometrial carcinoma diagnosed as FIGO stages I and Ⅱ Methods To analyze 112 early staged endometrial carcinoma cases admitted from Jan 1,1991 to Dec 30,2000 retrospectively Clinical characters,treatment and survival rate of recurrent cases were compared with non-recurrent Results The recurrent rate is 9 82% (11/112) The median age was 62,which is older than non-recurrent patients( P =0 025) Stage of disease,histologic type of carcinoma and grade did not show significant difference between the two groups( P 0 05),except for depth of myometrial invasion( P 0 05) Women in recurrent group underwent similar operation as non-recurrent ones( P 0 05),and they had not received any chemotherapy before recurrent disease came out The interval time between primary therapy and recurrence is 12 months Sites of recurrent disease were 7 in pelvic,1 in vagina,1 in liver,1 in multiple organs (lungs,liver and brain),and 1 only showed raise in sera CA 125 with undetectable disease All recurrent cases underwent chemotherapy,radiotherapy,and progesterone treatment respectively Four of them died of recurrence,and 5-years survival rate was 67% Conclusions The recurrent rate of endometrial carcinoma stages I and Ⅱ is about 10% Most of the recurrent disease occurs in pelvic,and less often in distant organs Myometrial invasion should be one of indications for chemotherapy to prevent recurrence